We are analyzing https://link.springer.com/article/10.1007/s10549-004-2756-z.

Title:
Impact of metastatic estrogen receptor and progesterone receptor status on survival | Breast Cancer Research and Treatment
Description:
Hormone responsive breast cancer is usually determined by the presence of estrogen receptors (ER) or progesterone receptors (PR) on primary invasive breast cancers. Adjuvant and metastatic hormone therapy are recommended based on primary ER and PR determination. Little information is available to determine if primary hormone receptors correlate with metastatic disease and if survival is influenced by metastatic receptor status. We retrospectively compared primary to metastatic tumor ER and PR content from 200 metastatic breast cancer patients. ER and PR analyses were available in both primary and metastatic disease in 200 and 173 patients, respectively. There was a correlation between both the ER and PR in the primary and metastatic lesion (p < 0.001). However, in 60 of 200 (30%) patients, discordance between primary and metastatic ER was noted. Tumors from 68 of 173 (39.3%) showed discordance for PR. In 39 (19.5%) patients, the ER primary status was positive and metastatic status was negative and in 21 (10.5%) patients, the primary status was negative and metastatic status was positive. Survival from the time of metastatic diagnosis was calculated. Those patients with ER positive primary and metastatic tumors (Positive/Positive) or only the metastatic lesion (Negative/Positive) had similar median survival (1131 and 1111 days, respectively). However, patients with tumors that changed from positive primary to negative metastasis (Positive/Negative) experienced significantly shorter median survival (669 days, p < 0.05). Likewise, median survival (580 days) was significantly shorter for patients with primary and metastasis ER negative (Negative/Negative, p < 0.001) compared to Positive/Positive (p < 0.001) or compared to Negative/Positive (p < 0.02). The changes in PR status were not associated with a change in survival. We found a significant discordance between hormone receptor content of primary versus metastatic breast cancer. The ER status of the metastatic lesion was a better predictor of survival. Therefore, optimal metastatic treatment cannot be determined solely on primary ER and PR analysis.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Politics

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 8,149,968 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

cancer, breast, google, scholar, primary, receptor, metastatic, estrogen, status, survival, article, progesterone, receptors, res, hormone, therapy, content, lower, patients, oncol, discordance, access, human, endocrine, clin, treat, privacy, cookies, analysis, research, treatment, elyse, cincinnati, information, publish, search, cancers, positive, negative, recurrent, osborne, advanced, eur, data, log, journal, glass, bradley, blau, compared,

Topics {✒️}

berardo gm clark morrow ck osborne human breast cancer early breast cancer advanced breast cancer metastatic breast cancer recurrent breast cancer month download article/chapter primary breast cancer recurrent breast cancers phase iii study secondary breast carcinomas primary breast carcinomas asynchronous metastatic/recurrent sites breast cancer metastatic hormone therapy hormone receptor content hormone receptor status p53 mutation int full article pdf receptor expression discordance privacy choices/manage cookies metastatic estrogen receptor multiple intratumoral assays metastatic receptor status progesterone receptor eur buzdar jf robertson article lower progesterone receptor activity progesterone receptor concordance letrozole versus tamoxifen oestrogen receptor concentration estrogen receptor variants estrogen receptor mutations metastatic tumor er check access instant access optimal metastatic treatment progesterone receptor status european economic area related subjects gazder dl stahl hollander da wolfe goldhirsch wh hartmann molteni rb duda kamby bb rasmussen heterogeneous gene alterations her2 gene amplification oestrogen receptor status conditions privacy policy

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Impact of metastatic estrogen receptor and progesterone receptor status on survival
         description:Hormone responsive breast cancer is usually determined by the presence of estrogen receptors (ER) or progesterone receptors (PR) on primary invasive breast cancers. Adjuvant and metastatic hormone therapy are recommended based on primary ER and PR determination. Little information is available to determine if primary hormone receptors correlate with metastatic disease and if survival is influenced by metastatic receptor status. We retrospectively compared primary to metastatic tumor ER and PR content from 200 metastatic breast cancer patients. ER and PR analyses were available in both primary and metastatic disease in 200 and 173 patients, respectively. There was a correlation between both the ER and PR in the primary and metastatic lesion (p < 0.001). However, in 60 of 200 (30%) patients, discordance between primary and metastatic ER was noted. Tumors from 68 of 173 (39.3%) showed discordance for PR. In 39 (19.5%) patients, the ER primary status was positive and metastatic status was negative and in 21 (10.5%) patients, the primary status was negative and metastatic status was positive. Survival from the time of metastatic diagnosis was calculated. Those patients with ER positive primary and metastatic tumors (Positive/Positive) or only the metastatic lesion (Negative/Positive) had similar median survival (1131 and 1111 days, respectively). However, patients with tumors that changed from positive primary to negative metastasis (Positive/Negative) experienced significantly shorter median survival (669 days, p < 0.05). Likewise, median survival (580 days) was significantly shorter for patients with primary and metastasis ER negative (Negative/Negative, p < 0.001) compared to Positive/Positive (p < 0.001) or compared to Negative/Positive (p < 0.02). The changes in PR status were not associated with a change in survival. We found a significant discordance between hormone receptor content of primary versus metastatic breast cancer. The ER status of the metastatic lesion was a better predictor of survival. Therefore, optimal metastatic treatment cannot be determined solely on primary ER and PR analysis.
         datePublished:
         dateModified:
         pageStart:65
         pageEnd:70
         sameAs:https://doi.org/10.1007/s10549-004-2756-z
         keywords:
            Breast cancer
            estrogen receptors
            hormone therapy
            metastatic hormone receptors
            Oncology
         image:
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:90
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Elyse E. Lower
               affiliation:
                     name:University of Cincinnati College of Medicine
                     address:
                        name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
                        type:PostalAddress
                     type:Organization
                     name:Oncology–Hematology Care
                     address:
                        name:Oncology–Hematology Care, Cincinnati, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Cincinnati Medical Center
                     address:
                        name:University of Cincinnati Medical Center, Cincinnati, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Eleanor L. Glass
               affiliation:
                     name:University of Cincinnati College of Medicine
                     address:
                        name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Deborah A. Bradley
               affiliation:
                     name:University of Cincinnati College of Medicine
                     address:
                        name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robbin Blau
               affiliation:
                     name:Oncology–Hematology Care
                     address:
                        name:Oncology–Hematology Care, Cincinnati, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sue Heffelfinger
               affiliation:
                     name:Oncology–Hematology Care
                     address:
                        name:Oncology–Hematology Care, Cincinnati, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Impact of metastatic estrogen receptor and progesterone receptor status on survival
      description:Hormone responsive breast cancer is usually determined by the presence of estrogen receptors (ER) or progesterone receptors (PR) on primary invasive breast cancers. Adjuvant and metastatic hormone therapy are recommended based on primary ER and PR determination. Little information is available to determine if primary hormone receptors correlate with metastatic disease and if survival is influenced by metastatic receptor status. We retrospectively compared primary to metastatic tumor ER and PR content from 200 metastatic breast cancer patients. ER and PR analyses were available in both primary and metastatic disease in 200 and 173 patients, respectively. There was a correlation between both the ER and PR in the primary and metastatic lesion (p < 0.001). However, in 60 of 200 (30%) patients, discordance between primary and metastatic ER was noted. Tumors from 68 of 173 (39.3%) showed discordance for PR. In 39 (19.5%) patients, the ER primary status was positive and metastatic status was negative and in 21 (10.5%) patients, the primary status was negative and metastatic status was positive. Survival from the time of metastatic diagnosis was calculated. Those patients with ER positive primary and metastatic tumors (Positive/Positive) or only the metastatic lesion (Negative/Positive) had similar median survival (1131 and 1111 days, respectively). However, patients with tumors that changed from positive primary to negative metastasis (Positive/Negative) experienced significantly shorter median survival (669 days, p < 0.05). Likewise, median survival (580 days) was significantly shorter for patients with primary and metastasis ER negative (Negative/Negative, p < 0.001) compared to Positive/Positive (p < 0.001) or compared to Negative/Positive (p < 0.02). The changes in PR status were not associated with a change in survival. We found a significant discordance between hormone receptor content of primary versus metastatic breast cancer. The ER status of the metastatic lesion was a better predictor of survival. Therefore, optimal metastatic treatment cannot be determined solely on primary ER and PR analysis.
      datePublished:
      dateModified:
      pageStart:65
      pageEnd:70
      sameAs:https://doi.org/10.1007/s10549-004-2756-z
      keywords:
         Breast cancer
         estrogen receptors
         hormone therapy
         metastatic hormone receptors
         Oncology
      image:
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:90
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Elyse E. Lower
            affiliation:
                  name:University of Cincinnati College of Medicine
                  address:
                     name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
                     type:PostalAddress
                  type:Organization
                  name:Oncology–Hematology Care
                  address:
                     name:Oncology–Hematology Care, Cincinnati, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Cincinnati Medical Center
                  address:
                     name:University of Cincinnati Medical Center, Cincinnati, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Eleanor L. Glass
            affiliation:
                  name:University of Cincinnati College of Medicine
                  address:
                     name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Deborah A. Bradley
            affiliation:
                  name:University of Cincinnati College of Medicine
                  address:
                     name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robbin Blau
            affiliation:
                  name:Oncology–Hematology Care
                  address:
                     name:Oncology–Hematology Care, Cincinnati, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sue Heffelfinger
            affiliation:
                  name:Oncology–Hematology Care
                  address:
                     name:Oncology–Hematology Care, Cincinnati, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:90
Organization:
      name:Kluwer Academic Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Cincinnati College of Medicine
      address:
         name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
         type:PostalAddress
      name:Oncology–Hematology Care
      address:
         name:Oncology–Hematology Care, Cincinnati, USA
         type:PostalAddress
      name:University of Cincinnati Medical Center
      address:
         name:University of Cincinnati Medical Center, Cincinnati, USA
         type:PostalAddress
      name:University of Cincinnati College of Medicine
      address:
         name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
         type:PostalAddress
      name:University of Cincinnati College of Medicine
      address:
         name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
         type:PostalAddress
      name:Oncology–Hematology Care
      address:
         name:Oncology–Hematology Care, Cincinnati, USA
         type:PostalAddress
      name:Oncology–Hematology Care
      address:
         name:Oncology–Hematology Care, Cincinnati, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Elyse E. Lower
      affiliation:
            name:University of Cincinnati College of Medicine
            address:
               name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
               type:PostalAddress
            type:Organization
            name:Oncology–Hematology Care
            address:
               name:Oncology–Hematology Care, Cincinnati, USA
               type:PostalAddress
            type:Organization
            name:University of Cincinnati Medical Center
            address:
               name:University of Cincinnati Medical Center, Cincinnati, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Eleanor L. Glass
      affiliation:
            name:University of Cincinnati College of Medicine
            address:
               name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
               type:PostalAddress
            type:Organization
      name:Deborah A. Bradley
      affiliation:
            name:University of Cincinnati College of Medicine
            address:
               name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
               type:PostalAddress
            type:Organization
      name:Robbin Blau
      affiliation:
            name:Oncology–Hematology Care
            address:
               name:Oncology–Hematology Care, Cincinnati, USA
               type:PostalAddress
            type:Organization
      name:Sue Heffelfinger
      affiliation:
            name:Oncology–Hematology Care
            address:
               name:Oncology–Hematology Care, Cincinnati, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
      name:Oncology–Hematology Care, Cincinnati, USA
      name:University of Cincinnati Medical Center, Cincinnati, USA
      name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
      name:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati
      name:Oncology–Hematology Care, Cincinnati, USA
      name:Oncology–Hematology Care, Cincinnati, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(69)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.15s.

LINK . SPRINGER . COM {}